{"data":{"id":"us-in/ic-16-42-26.5-2","jurisdiction":"us-in","citation":"IC 16-42-26.5-2","heading":"\"Individualized investigational treatment\"","body":"Sec. 2. As used in this chapter, \"individualized investigational treatment\" means a drug, biological product, or device that is unique to and produced exclusively for use by an individual patient, based on the individual's own genetic profile. The term includes individualized gene therapy, antisense oligonucleotides (ASO), and individualized neoantigen vaccines.","path":["TITLE 16. HEALTH","ARTICLE 42. REGULATION OF FOOD, DRUGS, AND COSMETICS","Chapter 26.5. Individualized Investigational Treatment"],"source_url":"https://iga.in.gov/ic/2026/Title_16.html#16-42-26.5-2","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-11T20:02:18Z","sha256":"8fba52f612ddc2df5000e880846462b59d0b83d88e449114033c385310dfaba6","source_id":"us-in","stale":false,"prev":"us-in/ic-16-42-26.5-1","next":"us-in/ic-16-42-26.5-3"},"notice":"GroundRules: Original legal text. Not legal advice."}